Nakatani A - Search Results

1

Investigating the Therapeutic Potential of LSD1 Enzyme Activity-Specific Inhibition by TAK-418 for Social and Memory Deficits in Rodent Disease Models.

Baba R, Matsuda S, Maeda R, Murakami K, Yamamoto Y, Nakatani A, Kimura H. Baba R, et al. Among authors: nakatani a. ACS Chem Neurosci. 2022 Feb 2;13(3):313-321. doi: 10.1021/acschemneuro.1c00713. Epub 2022 Jan 21. ACS Chem Neurosci. 2022. PMID: 35061371 Free article.

2

LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models.

Baba R, Matsuda S, Arakawa Y, Yamada R, Suzuki N, Ando T, Oki H, Igaki S, Daini M, Hattori Y, Matsumoto S, Ito M, Nakatani A, Kimura H. Baba R, et al. Among authors: nakatani a. Sci Adv. 2021 Mar 12;7(11):eaba1187. doi: 10.1126/sciadv.aba1187. Print 2021 Mar. Sci Adv. 2021. PMID: 33712455 Free PMC article.

3

The phosphodiesterase 10A selective inhibitor, TAK-063, induces c-Fos expression in both direct and indirect pathway medium spiny neurons and sub-regions of the medial prefrontal cortex in rats.

Nakatani A, Nakamura S, Kimura H. Nakatani A, et al. Neurosci Res. 2017 Dec;125:29-36. doi: 10.1016/j.neures.2017.06.007. Epub 2017 Jul 4. Neurosci Res. 2017. PMID: 28687229

4

In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M₁ Receptor, and Xanomeline, an Agonist of Muscarinic M₁/M₄ Receptor, in Rodents.

Mandai T, Kasahara M, Kurimoto E, Tanaka M, Suzuki M, Nakatani A, Kimura H. Mandai T, et al. Among authors: nakatani a. Neuroscience. 2019 Aug 21;414:60-76. doi: 10.1016/j.neuroscience.2019.07.003. Epub 2019 Jul 9. Neuroscience. 2019. PMID: 31299348

5

Inhibition of KDM1A activity restores adult neurogenesis and improves hippocampal memory in a mouse model of Kabuki syndrome.

Zhang L, Pilarowski G, Pich EM, Nakatani A, Dunlop J, Baba R, Matsuda S, Daini M, Hattori Y, Matsumoto S, Ito M, Kimura H, Bjornsson HT. Zhang L, et al. Among authors: nakatani a. Mol Ther Methods Clin Dev. 2021 Feb 18;20:779-791. doi: 10.1016/j.omtm.2021.02.011. eCollection 2021 Mar 12. Mol Ther Methods Clin Dev. 2021. PMID: 33738331 Free PMC article.

6

Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents.

Harada A, Kaushal N, Suzuki K, Nakatani A, Bobkov K, Vekich JA, Doyle JP, Kimura H. Harada A, et al. Among authors: nakatani a. Int J Neuropsychopharmacol. 2020 Feb 1;23(2):96-107. doi: 10.1093/ijnp/pyz056. Int J Neuropsychopharmacol. 2020. PMID: 31689714 Free PMC article.

7

Transgenic mice overexpressing miR-137 in the brain show schizophrenia-associated behavioral deficits and transcriptome profiles.

Arakawa Y, Yokoyama K, Tasaki S, Kato J, Nakashima K, Takeyama M, Nakatani A, Suzuki M. Arakawa Y, et al. Among authors: nakatani a. PLoS One. 2019 Jul 30;14(7):e0220389. doi: 10.1371/journal.pone.0220389. eCollection 2019. PLoS One. 2019. PMID: 31361772 Free PMC article.

8

Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors.

Fushimi M, Fujimori I, Wakabayashi T, Hasui T, Kawakita Y, Imamura K, Kato T, Murakami M, Ishii T, Kikko Y, Kasahara M, Nakatani A, Hiura Y, Miyamoto M, Saikatendu K, Zou H, Lane SW, Lawson JD, Imoto H. Fushimi M, et al. Among authors: nakatani a. J Med Chem. 2019 May 23;62(10):4915-4935. doi: 10.1021/acs.jmedchem.8b01630. Epub 2019 May 3. J Med Chem. 2019. PMID: 31009559

9

Low molecular weight chitosan prevents the progression of low dose streptozotocin-induced slowly progressive diabetes mellitus in mice.

Kondo Y, Nakatani A, Hayashi K, Ito M. Kondo Y, et al. Among authors: nakatani a. Biol Pharm Bull. 2000 Dec;23(12):1458-64. doi: 10.1248/bpb.23.1458. Biol Pharm Bull. 2000. PMID: 11145178

10

New model of progressive non-insulin-dependent diabetes mellitus in mice induced by streptozotocin.

Ito M, Kondo Y, Nakatani A, Naruse A. Ito M, et al. Among authors: nakatani a. Biol Pharm Bull. 1999 Sep;22(9):988-9. doi: 10.1248/bpb.22.988. Biol Pharm Bull. 1999. PMID: 10513628

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

207 results

Search Page